Syndax Pharmaceuticals (SNDX) Reports Q2 Loss of $0.47/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
August 9, 2016 6:30 AM EDTExpanded pipeline with potentially best-in-class, IND-ready anti-CSF-1R antibody
Progressing to Phase 2 of ENCORE 601 in NSCLC and Melanoma
Initiated ENCORE 602 for TNBC in collaboration with Genentech in June 2016
WALTHAM, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) --  Syndax Pharmaceuticals (Syndax, the Company or we) (Nasdaq: SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the second quarter ended June 30, 2016 and provided a pipeline update as well as a review of upcoming milestones. As of June 30, 2016, Syndax had $125.5 million... More
